变应性鼻炎患者特异性免疫治疗后的疗效分析  

The analysis of the efficacy of patients with allergic rhinitis treated with specific immunotherapy

作　　者：丁俊杰[1] 张建华[1] 陈斌[2] 

机构地区：[1]江苏大学附属上海市第八人民医院耳鼻咽喉科,上海200235 [2]上海交通大学附属第六人民医院耳鼻咽喉科

出　　处：《临床耳鼻咽喉头颈外科杂志》2014年第5期293-296,共4页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

摘　　要：目的:对35例变应性鼻炎患者接受标准化尘螨变应原疫苗特异性免疫治疗后的疗效及安全性进行评价。方法:对35例变应性鼻炎患者行特异性免疫治疗,比较治疗前与治疗1、2年后的症状、体征评分及视觉模拟量表(VAS)评分。结果:经过1年免疫治疗后患者的症状、体征评分及VAS评分较治疗前有显著降低(P<0.05);坚持完成2年治疗后患者的症状、体征评分及VAS评分较治疗前、治疗1年时亦有显著降低,三者之间差异有统计学意义(P<0.05)。结论:标准化尘螨变应原疫苗治疗对于该地区常年性变应性鼻炎是一种安全、有效的方法,可作为变应性鼻炎的一种常规治疗。为进一步提高疗效,建议完成至少2年的免疫治疗。Objective：To evaluatethe efficacy and safety of standardized subcutaneous immunotherapy for dust mite in patients with allergic rhinitis. Method：Using self-control methods, 35 cases with allergic rhinitis were trea- ted with specific immunotherapy for 2 years. Symptom score and visual analogue scale（VAS） score were observed before treatment and 1 years, 2 years after treatment respectively. Result：The symptoms, signs and VAS score of the 35 patients who were treated with specific immunotherapy after 1 year were significantly reduced than that he- fore treatment, the differences were statistically significant（P〈0.05）. The symptoms, signs and VAS score of the patients who completed 2 years＇ treatment, compared with that of pretreatment and l year treatment were sig- nificantly reduced, the differences were statistically significant（P〈0.05）. Conclusion：Standardized immunotherapy for dust mite is a safe, effective method for patients with perennial allergic rhinitis, which can be Used as a routine treatment for allergic rhinitis. To further improve the therapeutic effect, immunotherapy should be continued for at least 2 years.

关 键 词：特异性免疫治疗 变应原疫苗 鼻炎 变应性 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]